PDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.
3 reports, 3 independent
Updated Oct 15
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
PDS Biotechnology and the National Cancer Institute entered into a collaborative R&D agreement.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.NCI trials using PDS0301 and FDA discussions influencing Phase III plans.1 source
PDS Biotechnology and NCI established a collaborative R&D agreement for oncology research.1 source
NCI/NIH establishes collaborative R&D agreement with BioTech and appoints Chief of Surgical Oncology Section.1 source
Keep exploring
The entities involved
-
PDS Biotechnology (United States)
company in Lawrenceburg, United States
Nothing else this week.
-
National Cancer Institute
public hospital in Milan dedicated to cancer care
Nothing else this week.
-
National Institutes of Health
government organization in Shah Alam, Malaysia
-
BioTech
company in Prague, Czechia
Nothing else this week.
Coverage
Newest first; wire copies grouped- tickerreport.com
- Clinical Trials ArenaPDS Biotechnology completes recruitment for stage one of colorectal cancer trial PDS Biotechnology has completed subject recruitment for stage one of its open-label Phase II trial, evaluating the sys
- GlobeNewswirePDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results Metastatic Colorectal Cancer Cohort in